- Location
oral anticoagulant
"-
Bayer HealthCare Has Failed to Win The Backing of The US FDA's Cardiovascular
Jan 20, 2014Bayer HealthCare has failed to win the backing of the US FDA's Cardiovascular and Renal Drugs Advisory Committee to expand the use of its oral anticoagulant Xarelto (rivaroxaban) 2.5 mg twice daily (BID) in combination with standard ...
Tags: FDA Panel, ACS Patients
-
Bristol-Myers Squibb and Pfizer Have Announced The US FDA's Approval for Eliquis
Jan 4, 2013Bristol-Myers Squibb and Pfizer have announced the US FDA's approval for Eliquis (apixaban), used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In 2007, Pfizer and Bristol-Myers ...
Tags: US, FDA, Eliquis, patients, nonvalvular atrial fibrillation
-
Boston Scientific Completes Enrolling Patients in Its Prevail Confirmatory Study
Dec 17, 2012Boston Scientific, a provider of cardiovascular implants, has completed enrolling patients in its Prevail confirmatory study. The CE-marked self-expanding nitinol frame Watchman device, placed in the left atrial appendage (LAA) via the ...
Tags: Boston Scientific, cardiovascular implants, Prevail confirmatory study
-
Janssen Research & Development Has Submitted Supplemental New Drug Applications
Dec 5, 2012Janssen Research & Development has submitted supplemental New Drug Applications (sNDAs) to the US Food and Drug Administration (FDA) for the use of Xarelto (rivaroxaban), an oral anticoagulant. Janssen said the drug is used to treat ...
Tags: Xarelto, rivaroxaban, DVT, pulmonary embolism, VTE
-
Janssen Research & Development Has Submitted a Supplemental New Drug Application
Dec 3, 2012Janssen Research & Development has submitted a supplemental new drug application (sNDA) with FDA, seeking approval to use Xarelto (rivaroxaban), an oral anticoagulant, to reduce the risk of stent thrombosis in patients with acute coronary ...
-
The European Commission Has Cleared an Oral Anticoagulant, Eliquis
Nov 28, 2012The European Commission has cleared an oral anticoagulant, Eliquis, developed by Bristol-Myers Squibb (BMS) and Pfizer. Eliquis 5mg, trade name of apixaban in Europe, is indicated as a twice-daily drug for preventing strokes and systemic ...
Tags: BMS-Pfizer Oral Anticoagulant, oral anticoagulant, Eliquis, apixaban
-
Bayer Oral Anticoagulant Xarelto Has Gained Positive CDR Recommendation
Nov 28, 2012Bayer oral anticoagulant Xarelto has gained positive common drug review (CDR) recommendation from the Canadian Agency for Drugs and Technologies in Health for the prevention of stroke and systemic embolism in atrial fibrillation (AF) ...
Tags: Bayer oral anticoagulant Xarelto, CDR Recommendation, Stroke Prevention
